NASDAQ:PACB - Pacific Biosciences of California Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.60
  • Forecasted Upside: -16.55 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$13.90
▲ +0.13 (0.94%)
1 month | 3 months | 12 months
Get New Pacific Biosciences of California Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PACB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PACB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.60
▼ -16.55% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Pacific Biosciences of California in the last 3 months. The average price target is $11.60, with a high forecast of $17.00 and a low forecast of $7.00. The average price target represents a -16.55% upside from the last price of $13.90.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Pacific Biosciences of California.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/5/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/3/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/1/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2020Cantor FitzgeraldBoost Price TargetOverweight$11.00 ➝ $17.00High
i
Rating by Kyle Mikson CFA at Cantor Fitzgerald
10/2/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$15.00Low
i
10/1/2020Piper SandlerBoost Price TargetOverweight$6.00 ➝ $12.00High
i
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$7.00Low
i
6/10/2020Cantor FitzgeraldReiterated RatingBuy$5.00High
i
Rating by Kyle Mikson CFA at Cantor Fitzgerald
6/1/2020Cantor FitzgeraldInitiated CoverageBuy$5.00High
i
Rating by Craig Bijou at Cantor Fitzgerald
5/7/2020Piper SandlerLower Price TargetOverweight$7.00 ➝ $6.00Medium
i
4/17/2020Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by C. Bijou at Cantor Fitzgerald
3/9/2020Cantor FitzgeraldReiterated RatingOverweight$5.00Medium
i
Rating by C. Bijou at Cantor Fitzgerald
12/18/2019Piper Jaffray CompaniesReiterated RatingBuy$7.00Low
i
Rating by William Quirk at Piper Jaffray Companies
10/15/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$8.00High
i
6/20/2019Cantor FitzgeraldSet Price TargetHold$8.00Low
i
Rating by Jordan Abrams at Cantor Fitzgerald
6/13/2019Cantor FitzgeraldReiterated RatingHoldLow
i
Rating by Jordan Abrams at Cantor Fitzgerald
5/3/2019Cantor FitzgeraldReiterated RatingHold$8.00Low
i
Rating by J. Abrams at Cantor Fitzgerald
4/2/2019StephensDowngradeOverweight ➝ Equal Weight$4.50 ➝ $8.00Low
i
1/4/2019CowenDowngradeOutperform ➝ Market PerformLow
i
11/12/2018Cantor FitzgeraldDowngradeOverweight ➝ Neutral$8.00Low
i
Rating by Jordan Abrams at Cantor Fitzgerald
11/1/2018Cantor FitzgeraldSet Price TargetBuy$8.00Medium
i
Rating by Jordan Abrams at Cantor Fitzgerald
10/21/2018Cantor FitzgeraldReiterated RatingBuy$8.00Low
i
Rating by Jordan Abrams at Cantor Fitzgerald
10/19/2018CowenInitiated CoverageOutperform ➝ Outperform$6.50High
i
10/11/2018Cantor FitzgeraldSet Price TargetBuy$8.00Medium
i
Rating by Jordan Abrams at Cantor Fitzgerald
8/8/2018Cantor FitzgeraldInitiated CoverageOverweight$5.00High
i
8/3/2018Piper Jaffray CompaniesReiterated RatingHold$3.80High
i
11/3/2017First AnalysisDowngradeOverweight ➝ Equal Weight$4.00N/A
i
9/28/2017CL KingDowngradeBuy ➝ Neutral$6.80High
i
4/27/2017Cantor FitzgeraldSet Price TargetBuy$8.00Medium
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
2/3/2017Cantor FitzgeraldReiterated RatingBuy$8.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
12/18/2016Cantor FitzgeraldSet Price TargetBuy$8.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
12/16/2016Cantor FitzgeraldReiterated RatingOverweight$15.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$12.00N/A
i
11/3/2016Cantor FitzgeraldLower Price TargetBuy$18.00 ➝ $15.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
10/24/2016Cantor FitzgeraldSet Price TargetBuy$18.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
6/29/2016Cantor FitzgeraldReiterated RatingBuy$18.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
6/27/2016CL KingInitiated CoverageBuy$11.00N/A
i
4/15/2016MKM PartnersInitiated CoverageNeutral$16.50N/A
i
4/14/2016First AnalysisInitiated CoverageOverweight$11.00N/A
i
2/5/2016StephensReiterated RatingBuyN/A
i
Rating by Drew Jones at Stephens
2/4/2016JPMorgan Chase & Co.Boost Price Target$10.00 ➝ $12.00N/A
i
2/4/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$9.00 ➝ $11.00N/A
i
2/3/2016Cantor FitzgeraldReiterated RatingBuy$18.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
1/4/2016Cantor FitzgeraldBoost Price TargetBuy$11.00 ➝ $18.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
(Data available from 10/26/2015 forward)
Pacific Biosciences of California logo
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $13.90
$13.33
$13.91

50 Day Range

MA: $10.20
$6.35
$14.95

52 Week Range

Now: $13.90
$2.20
$15.12

Volume

2,359,700 shs

Average Volume

2,556,808 shs

Market Capitalization

$2.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7